Project Grant R01NS148478
- The National Institute of Neurological Disorders and Stroke awarded the University of Illinois $225,474 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop a base editing gene therapy for Parkinson's disease by modulating LRRK2. The project develops a genome editing approach using intein-split base editors delivered by adeno-associated viruses to silence LRRK2 expression or precisely modulate its activity. In...
- The National Institute on Aging awarded The Trustees of Columbia University in the City of New York $452,375 on June 15, 2026, under the Aging Research program (CFDA 93.866) to develop gene therapy targeting non-motor defects in synucleinopathy. The project addresses gastrointestinal dysfunction in Parkinson's disease and related synucleinopathies by investigating alpha-synuclein pathology in the enteric nervous system. The research employs single-chain variable fragments (scFvs)—antibody...
- The National Institute of Neurological Disorders and Stroke awarded Brigham and Women's Hospital $492,250 on August 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to identify the palmitoyltransferase for glucocerebrosidase trafficking receptor LIMP2 and restore GBA1 function in Parkinson disease and Lewy body dementia. The research investigates palmitoylation—modification of proteins by the fatty acid palmitate—as a...
- The National Institute of Neurological Disorders and Stroke awarded the University of Georgia Research Foundation $1,297,188 on May 8, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate neuroinflammatory epitranscriptomic mechanisms in Parkinson's disease. The research examines the role of the ALKBH5 demethylase enzyme in microglial neuroinflammatory responses triggered by alpha-synuclein aggregates, a hallmark...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded The Johns Hopkins University a $155,000 project grant effective July 8, 2025 through June 30, 2027 under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The award supports the characterization of an aminoacyl-tRNA synthetase complex interacting multifunctional protein-2 (AIMP2) variant-linked mouse model of Parkinson's disease. The...
- The National Institute of Neurological Disorders and Stroke awarded the University of Connecticut Health Center $1.815 million on August 3, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to support research on the regulation of beta-glucocerebrosidase in Parkinson's disease and related dementias. The research examines how the protein GCIP1 regulates beta-glucocerebrosidase (GCase) processing, trafficking, and maturation in...
- The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded a cooperative agreement to The Johns Hopkins University for $749,720 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The funding supports development and preclinical testing of a sustained-delivery insulin-like growth factor 1 (IGF-1) therapeutic for...
- The National Institute of Neurological Disorders and Stroke awarded Northwestern University $566,529 on April 24, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate age-related deficits in trophic support of dopamine neurons in preclinical models of Parkinson's disease. The research examines cell-type-specific alterations in LRRK2G2019S mice to determine how the LRRK2 mutation affects neuroprotective signaling...
- The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded $418,489 to the University of Florida on September 1, 2026, for exploration of potential treatments targeting alpha-synuclein in Parkinson's disease under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research to develop novel therapeutics for Parkinson's disease,...
- Federal Project Grant Award Summary Van Andel Research Institute (VAI) received a Project Grant award of $1,009,212 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective July 4, 2025, with completion targeted for June 30, 2027. The award supports research and development activities focused on a novel gene therapy approach to mitigate neurotoxicity in...
The National Institute of Neurological Disorders and Stroke awarded The Johns Hopkins University $646,509 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop novel non-viral gene therapy for Parkinson's disease. The award funds research on GBA1 gene therapy to enhance glucocerebrosidase (gcase) activity in the midbrain as a disease-modifying intervention for Parkinson's disease and dementia with Lewy bodies. The project employs a complementary delivery strategy combining focused ultrasound–mediated blood-brain barrier opening and barrier-breaching biodegradable nanoparticles with promoter optimization to enable systemic gene transfer via minimally invasive administration. This approach addresses limitations of adeno-associated virus vectors, including liver toxicity, immunogenicity, limited packaging capacity, and high cost. The research builds on pilot data showing that intracranial administration of patented nanoparticles carrying GBA1 plasmid reduces Lewy body–like pathology and motor symptoms in an alpha-synuclein preformed fibril–induced mouse model of sporadic Parkinson's disease. Aim 1 investigates expression and safety of GBA1 plasmids with different promoters delivered via nanoparticles, administered either locally through convection-enhanced delivery or systemically via tail vein injection combined with focused ultrasound–mediated blood-brain barrier opening, and characterizes the physicochemical properties and physiological stability of these nanoparticles. Work is performed in Baltimore, Maryland, with a period of performance from September 1, 2026, through August 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $646.5k | 8/31/26 |